[1] Chen, T. T. (2013). “Statistical issues and challenges in immuno-oncology”. Journal for ImmunoTherapy of Cancer, 1, 1-18.

[2] Callegaro, A. and Spiessens, B. (2017), Testing Treatment Effect in Randomized Clinical Trials With Possible Nonproportional Hazards, *Statistics in Biopharmaceutical Research,* VOL.9, NO.2, 204–211

[3] Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ. (2017), Interpretability of Cancer Clinical Trials Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. *JAMA Oncology*; Vol.3(12), pp.1692-1696

[4] Rufibach, K. (2018). Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond. Pharm Stat 1-21.

[5] Huang, B. and Kuan, P.-F. (2018), Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point, *Pharmaceutical Statistics*;17:202–213

[6] Uno H, Claggett B, Tian L, et al. (2014), Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. *J Clin Oncol*; 32(22):2380-2385.

[7] ICH HARMONISED GUIDELINE (2019), Addendum on Estimands and Sensitivity Analysis in Clinical Trials E9(R1). https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf

[8] Horiguchi M, Cronin AM, Takeuchi M, Uno H. (2018) A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time‐to‐event data in randomized clinical trials. *Statistics in Medicine*.;37: 2307–2320.

[9] Chappell R, Zhu X. (2016), Describing differences in survival curves. *JAMA Oncol*.; 2: 906–907.

[10] Irwin, J. O. (1949), The Standard Error of an Estimate of Expectational Life, *Journal of Hygiene*, 47, 188-189.

[11] Karrison, T. (1987), Restricted Mean Life With Adjustment for Covariates,* Journal of the American Statistical Association*, 82, 1169-1176.

[12] Karrison, T. (1997), Use of Irwin's Restricted Mean Life as an Index for Comparing Survival in Different Treatment Groups, *Controlled Clinical Trials*, 18, 151-167.

[13] Zucker D. (1998), Restricted mean life with covariates: modification and extension of a useful survival analysis method*. J Am Stat Assoc*; 93:702-709.

[14] Messori A, Damuzzo V, Leonardi L, Agnoletto L, Chiumente M, Mengato D. CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Feb 19.

[15] Chiumente M, Mengato D, Messori A. Tisagenlecleucel in Non-Hodgkin Lymphoma:The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median. Acta Haematol. 2020 Feb 19:1-2.

[16] Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A. Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors. Front Oncol. 2019 Jun 4;9:453.

[17] Trinquart L, Jacot J, Conner S, Porcher R. (2016), Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. *J Clin Oncol*;34(15):1813-1819.

[18] Zhao L, Claggett B, Tian L, et al. (2016), On the restricted mean survival time curve in survival analysis. *Biometrics*; 72:215-221.

[19] Peto, R., et. al. (1977), DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL TRIALS REQUIRING PROLONGED OBSERVATION OF EACH PATIENT, Br. J. Cancer, 35, 1—39.

[20] Liao, J.J.Z., and Liu, G.F. (2019), A Flexible Survival Model for Fitting Time to Event Data in Clinical Trials. *Pharmaceutical Statistics, 1–13. https://doi.org/10.1002/pst.1947*.

[21] Royston, P. and Parmar, M. K.B. (2013), Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome, *BMC Medical Research Methodology*, 13:152

[22] Royston P, Parmar M. (2011), The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. *Stat Med*;30(19):2409-2421.

[23] Messori, A., Damuzzo, V., Agnoletto, L. et al. A Model-Independent Method to Determine Restricted Mean Survival Time in the Analysis of Survival Curves. SN Compr. Clin. Med. 2, 66-68 (2020).

[24] Tian, L., et al. (2018), Statistical Considerations For Non-Proportional Hazards Model in Immune-Oncology Trials. *Mini-Symposium on Biostatistics in Drug Development*, June 11, 2018, Beijing, China

[25] Huang, M., Liao, J.J.Z., and Kong, F. (2019), Novel Approaches for Survival Extrapolation for Oncology Health Technology Assessment (HTA), ICSA China Meeting, July 1-4, 2019, Tianjin, China.

[26] Pocock SJ, Clayton TC, Altman DG. (2002), Survival plots of time‐to‐event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686‐1689.

[27] Gebski V, Gares V, Gibbs E, Byth K. (2018), Data maturity ad follow‐up in time‐to‐event analyses. Int. J. Epidemiol. 2018;47(3):850‐859. https://doi.org/10.1093/ije/dyy013

[28] Kirkwood JM, Strawderman MH, Ernstoff, MS et al. (1996), Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684, *Journal of Clinical Oncology*, 14, 7-17.

[29] Grambsch, P. and Therneau, T. (1994), Proportional hazards tests and diagnostics based on weighted residuals. *Biometrika*, 81, 515-26.

[30] Uno H. (2015), Vignette for survRM2 package: comparing two survival curves using the restricted mean survival time. 2015.

[31] Uno, H., Tian, L., Cronin, A., Battioui, C., Horiguchi, M. (2017), Comparing Restricted Mean Survival Time: Package‘survRM2’. Version 1.0-2. https://cran.r-project.org/web/packages/survRM2/survRM2.pdf

[32] Ferris RL, Blumenschein G, Fayette J, et al. (2016), Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, *The New England Journal of Medicine*, 375, 19, 1856-1867, DOI: 10.1056/NEJMoa1602252

[33] Borghaei H, Paz-Ares L, Horn L et al., (2015), Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer, *The New England Journal of Medicine*, 373, 17, 1627-1639. DOI: 10.1056/NEJMoa1507643

[34] Tian L, Zhao L, Wei LJ. (2014) Predicting the restricted mean event time with the subject’s baseline covariates in survival analysis. *Biostatistics*, 15, 222-233.

[35] Karrison T and Kocherginsky M (2018). Restricted mean survival time: does covariate adjustment improve precision in randomized clinical trials? *Clinical Trials*, 15: 178-188.

[36] Liu, G.F., and Liao, J.J.Z. (2020), “Analysis of Time to Event Data using a Flexible Mixture Model under Proportional Hazards”, *J. of Biopharmaceutical Statistics*, doi.org/10.1080/10543406.2020.1783283

[37] Yang S, (2018) Improving testing and description of treatment effect in clinical trials with survival outcomes. *Statistics in Medicine*;1–15. https://doi.org/10.1002/sim.7676